Please select the option that best describes you:
How do you approach treatment sequencing in KRAS G12C NSCLC?
Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy?
Answer from: Medical Oncologist at Academic Institution
Sequencing is an excellent question that will require a little more time to be answered. There are currently multiple ongoing trials in this space but at the current moment, the approval of sotorasib is in the second line space and I would not use KRAS inhibitors as first line off study. That being ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I will use PD-L1 and co-mutational testing on next generation sequencing (NGS) to select therapeutic options. Specifically, if the tumor does not have a co-mutation in STK11/KEAP1, I will use PD-L1 to guide my decision of pembrolizumab with or without chemotherapy in the first line setting. If there...
Answer from: Medical Oncologist at Academic Institution
We await mature data from ongoing clinical trials evaluating first-line therapy of KRAS G12C inhibitors, either as monotherapy (CodeBreaK 201/KRYSTAL-7) or in combination with various agents, including immunotherapy (CodeBreaK 101/KRYSTAL-7) to name a few. Several other KRAS G12C inhibitors are in d...